Emergence of Candida auris infection: A review | ||
| Microbes and Infectious Diseases | ||
| Article 38, Volume 4, Issue 4, November 2023, Pages 1416-1427 PDF (758.02 K) | ||
| Document Type: Review Article | ||
| DOI: 10.21608/mid.2023.203444.1499 | ||
| Author | ||
| Rajan Paudel* | ||
| School of Health and Allied Sciences, Faculty of Health Sciences, Pokhara University, Pokhara, Nepal | ||
| Abstract | ||
| Background: Candida auris (C. auris), first described in 2009, is an emerging pathogenic fungus that has been documented globally with large outbreaks and high mortality rates associated with therapeutic failure. This is an important, multidrug-resistant, nosocomial pathogen causing invasive infections. The common therapeutic failures of C. auris infections are caused by laboratory misidentification and multi-drug resistance profiles. Widespread resistance to fluconazole, as well as variable susceptibilities to amphotericin B, echinocandins, and other azoles contributes to its infection. Because of multi drug resistance, improper antifungal medication use, persistence in hospital environments and treatment failure, the emergence of C. auris is alarming. Accurate identification, effective treatment strategies and implementation of infection control measures are crucial for the prevention and control of outbreaks. The aim of this review is to provide updated information and summarize the introduction, epidemiology, clinical characteristics, drug resistance, identification, therapeutic options, infection prevention and control, conclusive remarks and future prospective of C. auris. | ||
| Keywords | ||
| Key Words: Candida auris; multidrug resistant; emerging pathogen | ||
|
Statistics Article View: 817 PDF Download: 396 |
||
